The murine CC chemokine, 6C-kine, inhibits tumor growth and angiogenesis in a human lung cancer SCID mouse model
dc.contributor.author | Burdick, Marie D. | en_US |
dc.contributor.author | Strieter, Robert M. | en_US |
dc.contributor.author | Arenberg, Douglas A. | en_US |
dc.contributor.author | Zlotnick, Albert | en_US |
dc.contributor.author | Strom, Scott R. B. | en_US |
dc.date.accessioned | 2006-09-08T19:57:16Z | |
dc.date.available | 2006-09-08T19:57:16Z | |
dc.date.issued | 2001-01 | en_US |
dc.identifier.citation | Arenberg, Douglas A.; Zlotnick, Albert; Strom, Scott R. B.; Burdick, Marie D.; Strieter, Robert M.; (2001). "The murine CC chemokine, 6C-kine, inhibits tumor growth and angiogenesis in a human lung cancer SCID mouse model." Cancer Immunology, Immunotherapy 49(11): 587-592. <http://hdl.handle.net/2027.42/42085> | en_US |
dc.identifier.issn | 0340-7004 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/42085 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=11225989&dopt=citation | en_US |
dc.description.abstract | The recently described CC chemokine, 6C-kine, is unique in that it contains -six rather than the usual four conserved cysteines typical of this family. Furthermore, murine 6C-kine binds to one of the CXC chemokine receptors CXCR3, in addition to its other known receptor CCR7. We have shown that two other ligands of CXCR3, IP-10 and MIG, are potent inhibitors of tumor growth in severe combined immunodeficiency (SCID) mice. We postulated that murine 6C-kine may also inhibit tumor growth via inhibition of angiogenesis in this model. SCID mice ( n =6 per group) inoculated with A549 human lung cancer cells were treated with either 6C-kine (100 ng intra-tumor injection every other day) or control protein for 8 weeks. Tumors from murine 6C-kine-treated mice (288 ± 26 mm 3 ) were significantly smaller than tumors from control treated mice (788 ± 156 mm 3 , P =0.005). Additionally, murine 6C-kine reduced metastases compared with controls (0.5 ± 0.3 vs 3.0 ± 1.2 metastases per animal, P =0.05). Tumor vascularity (as assessed by vessel density counting) was reduced in murine 6C-kine-treated mice compared with controls. Murine 6C-kine had no direct effect on proliferation of A549 cells, and there were no differences in the infiltration of leukocyte sub-populations, assessed by flow cytometry, in the treatment groups. Interestingly, human 6C-kine, unlike murine 6C-kine, does not bind CXCR3 and had no anti-tumor effect in the same model. These data suggest that murine 6C-kine has anti-tumor effects independent of its leukocyte-recruiting activity. Furthermore, while not confirmatory, these data lend further support to the fact that CXCR3 may be the receptor for angiostatic CXC chemokines. | en_US |
dc.format.extent | 103120 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Springer-Verlag; Springer-Verlag Berlin Heidelberg | en_US |
dc.subject.other | Animal Models | en_US |
dc.subject.other | Key Words Cytokine | en_US |
dc.subject.other | Tumor | en_US |
dc.subject.other | Angiogenesis | en_US |
dc.subject.other | Legacy | en_US |
dc.title | The murine CC chemokine, 6C-kine, inhibits tumor growth and angiogenesis in a human lung cancer SCID mouse model | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Microbiology and Immunology | en_US |
dc.subject.hlbsecondlevel | Biological Chemistry | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, University of Michigan Medical School, Ann Arbor, MI 48109-0642, USA, US | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, University of Michigan Medical School, Ann Arbor, MI 48109-0642, USA, US | en_US |
dc.contributor.affiliationother | Department of Medicine, Division of Pulmonary & Critical Care Medicine, University of California Los Angeles (UCLA), Los Angeles, CA 90095-1690, USA, US | en_US |
dc.contributor.affiliationother | DNAX Research Institute, Palo Alto, CA 94394-1104, USA, US | en_US |
dc.contributor.affiliationother | Department of Medicine, Division of Pulmonary & Critical Care Medicine, University of California Los Angeles (UCLA), Los Angeles, CA 90095-1690, USA, US | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 11225989 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/42085/1/262-49-11-587_10490587.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/s002620000147 | en_US |
dc.identifier.source | Cancer Immunology, Immunotherapy | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.